Differential sensitivity of melanoma cell lines with differing B-Raf mutational status to the new oncogenic B-Raf kinase inhibitor UI-152

Cancer Letters

Volumn 320, Issue 2, 2012, Pages 215-224

  Kim, Yun Ki ^a   Ahn, Soon Kil ^a,b   Lee, Michael ^a  

^a SolarLight Ltd   (South Korea)

^b YOUAI Co Ltd   (South Korea)

Author keywords

Apoptosis; Autophagy; B Raf inhibitor; Melanoma; UI 152

Indexed keywords

3 METHYLADENINE; B RAF KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; UI 152; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; B RAF GENE; CONTROLLED STUDY; DRUG SELECTIVITY; GENE; GENE MUTATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

AUTOPHAGY; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; MAP KINASE SIGNALING SYSTEM; MELANOMA; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; PURINES; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84859596670     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.03.006     Document Type: Article

References (46)

1. Fecher L.A., Amaravadi R.K., Flaherty K.T. The MAPK pathway in melanoma. Curr. Opin. Oncol. 2008, 20:183-189.
2. Sullivan R.J., Atkins M.B. Molecular targeted therapy for patients with melanoma: the promise of MAPK pathway inhibition and beyond. Expert Opin. Invest. Drugs 2010, 19:1205-1216.
3. Emuss V., Garnett M., Mason C., Marais R. Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. Cancer Res. 2005, 65:9719-9726.
4. Dong J., Phelps R.G., Qiao R., Yao S., Benard O., Ronai Z., Aaronson S.A. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res. 2003, 63:3883-3885.
5. Gray-Schopfer V., Wellbrock C., Marais R. Melanoma biology and new targeted therapy. Nature 2007, 445:851-857.
6. Ribas A., Flaherty K.T. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat. Rev. Clin. Oncol. 2011, 8:426-432.
7. Karasarides M., Chiloeches A., Hayward R., Niculescu-Duvaz D., Scanlon I., Friedlos F., Ogilvie L., Hedley D., Martin J., Marshall C.J., Springer C.J., Marais R. B-RAF is a therapeutic target in melanoma. Oncogene 2004, 23:6292-6298.
8. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., Chen C., Zhang X., Vincent P., McHugh M., Cao Y., Shujath J., Gawlak S., Eveleigh D., Rowley B., Liu L., Adnane L., Lynch M., Auclair D., Taylor I., Gedrich R., Voznesensky A., Riedl B., Post L.E., Bollag G., Trail P.A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64:7099-7109.
9. Kane R.C., Farrell A.T., Saber H., Tang S., Williams G., Jee J.M., Liang C., Booth B., Chidambaram N., Morse D., Sridhara R., Garvey P., Justice R., Pazdur R. Sorafenib for the treatment of advanced renal cell carcinoma. Clin. Cancer Res. 2006, 12:7271-7278.
10. Lang L. FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology 2008, 134:379.
11. Eisen T., Ahmad T., Flaherty K.T., Gore M., Kaye S., Marais R., Gibbens I., Hackett S., James M., Schuchter L.M., Nathanson K.L., Xia C., Simantov R., Schwartz B., Poulin-Costello M., O'Dwyer P.J., Ratain M.J. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Brit. J. Cancer 2006, 95:581-586.
12. Ratain M.J., Eisen T., Stadler W.M., Flaherty K.T., Kaye S.B., Rosner G.L., Gore M., Desai A.A., Patnaik A., Xiong H.Q., Rowinsky E., Abbruzzese J.L., Xia C., Simantov R., Schwartz B., O'Dwyer P.J. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2006, 24:2505-2512.
13. Stuart D., Aardalen K., Venetsanakos E., Nagel T., Wallroth M., Batt D., Ramurthy S., Poon D., Faure M., Lorenzana E., Salangsang F., Dove J., Garrett E., Aikawa M., Kaplan A., Amiri P., Renhowe P. RAF265 is a potent Raf kinase inhibitor with selective anti-proliferative activity in vitro and in vivo. AACR Meeting Abst. 2008, 4876.
14. Tsai J., Lee J.T., Wang W., Zhang J., Cho H., Mamo S., Bremer R., Gillette S., Kong J., Haass N.K., Sproesser K., Li L., Smalley K.S., Fong D., Zhu Y.L., Marimuthu A., Nguyen H., Lam B., Liu J., Cheung I., Rice J., Suzuki Y., Luu C., Settachatgul C., Shellooe R., Cantwell J., Kim S.H., Schlessinger J., Zhang K.Y., West B.L., Powell B., Habets G., Zhang C., Ibrahim P.N., Hirth P., Artis D.R., Herlyn M., Bollag G. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. USA 2008, 105:3041-3046.
15. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., O'Dwyer P.J., Lee R.J., Grippo J.F., Nolop K., Chapman P.B. Inhibition of mutated, activated BRAF in metastatic melanoma. New Engl. J. Med. 2010, 363:809-819.
16. Hatzivassiliou G., Song K., Yen I., Brandhuber B.J., Anderson D.J., Alvarado R., Ludlam M.J., Stokoe D., Gloor S.L., Vigers G., Morales T., Aliagas I., Liu B., Sideris S., Hoeflich K.P., Jaiswal B.S., Seshagiri S., Koeppen H., Belvin M., Friedman L.S., Malek S. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010, 464:431-435.
17. Heidorn S.J., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho J.S., Springer C.J., Pritchard C., Marais R. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010, 140:209-221.
18. Ahn J.-H., Lee M. Suppression of autophagy sensitizes multidrug resistant cells towards Src tyrosine kinase specific inhibitor PP2. Cancer Lett. 2011, 310:188-197.
19. Poulikakos P.I., Zhang C., Bollag G., Shokat K.M., Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464:427-430.
20. Rushworth L.K., Hindley A.D., O'Neill E., Kolch W. Regulation and role of Raf-1/B-Raf heterodimerization. Mol. Cell. Biol. 2006, 26:2262-2272.
21. Kabeya Y., Mizushima N., Ueno T., Yamamoto A., Kirisako T., Noda T., Kominami E., Ohsumi Y., Yoshimori T. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000, 19:5720-5728.
22. Bjørkøy G., Lamark T., Johansen T. P62/SQSTM1: a missing link between protein aggregates and the autophagy machinery. Autophagy 2006, 2:138-139.
23. Shackelford D.B., Shaw R.J. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat. Rev. Cancer 2009, 9:563-575.
24. Schmelzle T., Hall M.N. TOR, a central controller of cell growth. Cell 2000, 103:253-262.
25. Cummings B.S., Schnellmann R.G. Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. J. Pharmacol. Exp. Ther. 2002, 302:8-17.
26. Solit D.B., Garraway L.A., Pratilas C.A., Sawai A., Getz G., Basso A., Ye Q., Lobo J.M., She Y., Osman I., Golub T.R., Sebolt-Leopold J., Sellers W.R., Rosen N. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439:358-362.
27. Tran N.H., Wu X., Frost J.A. B-raf and Raf-1 are regulated by distinct autoregulatory mechanisms. J. Biol. Chem. 2005, 280:16244-16253.
28. King A.J., Patrick D.R., Batorsky R.S., Ho M.L., Do H.T., Zhang S.Y., Kumar R., Rusnak D.W., Takle A.K., Wilson D.M., Hugger E., Wang L., Karreth F., Lougheed J.C., Lee J., Chau D., Stout T.J., May E.W., Rominger C.M., Schaber M.D., Luo L., Lakdawala A.S., Adams J.L., Contractor R.G., Smalley K.S., Herlyn M., Morrissey M.M., Tuveson D.A., Huang P.S. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res. 2006, 66:11100-11105.
29. Xie P., Streu C., Bregman H., Pagano N., Meggers E., Marmorstein R. The crystal structure of B-Raf in complex with an organoruthenium inhibitor reveals a mechanism for inhibition of an active form of B-Raf kinase. Biochemistry 2009, 48:5187-5198.
30. Halaban R., Zhang W., Bacchiocchi A., Cheng E., Parisi F., Ariyan S., Krauthammer M., McCusker J.P., Kluger Y., Sznol M. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res. 2010, 23:190-200.
31. Hu J., Yu H., Kornev A.P., Zhao J., Filbert E.L., Taylor S., Shaw A.S. Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF. Proc. Natl. Acad. Sci. USA 2011, 108:6067-6072.
32. Søndergaard J.N., Nazarian R., Wang Q., Guo D., Hsueh T., Mok S., Sazegar H., MacConaill L.E., Barretina J.G., Kehoe S.M., Attar N., von Euw E., Zuckerman J.E., Chmielowski B., Comin-Anduix B., Koya R.C., Mischel P.S., Lo R.S., Ribas A. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J. Transl. Med. 2010, 8:39.
33. Little A.S., Balmanno K., Sale M.J., Newman S., Dry J.R., Hampson M., Edwards P.A., Smith P.D., Cook S.J. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci. Signal. 2011, 4:ra17.
34. Kondo Y., Kanzawa T., Sawaya R., Kondo S. The role of autophagy in cancer development and response to therapy. Nat. Rev. Cancer 2005, 5:726-734.
35. Levine B. Unraveling the role of autophagy in cancer. Autophagy 2006, 2:65-66.
36. Kang C., Avery L. To be or not to be, the level of autophagy is the question: dual roles of autophagy in the survival response to starvation. Autophagy 2008, 4:82-84.
37. Maiuri M.C., Zalckvar E., Kimchi A., Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat. Rev. Mol. Cell Biol. 2007, 8:714-752.
38. Mizushima N., Levine B., Cuervo A.M., Klionsky D.J. Autophagy fights disease through cellular self-digestion. Nature 2008, 451:1069-1075.
39. Boya P., González-Polo R.A., Casares N., Perfettini J.L., Dessen P., Larochette N., Métivier D., Meley D., Souquere S., Yoshimori T., Pierron G., Codogno P., Kroemer G. Inhibition of macroautophagy triggers apoptosis. Mol. Cell. Biol. 2005, 25:1025-1040.
40. Jia L., Dourmashkin R.R., Allen P.D., Gray A.B., Newland A.C., Kelsey S.M. Inhibition of autophagy abrogates tumour necrosis factor alpha induced apoptosis in human T-lymphoblastic leukaemic cells. Brit. J. Haematol. 1997, 98:673-685.
41. Shimizu S., Kanaseki T., Mizushima N., Mizuta T., Arakawa-Kobayashi S., Thompson C.B., Tsujimoto Y. Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat. Cell Biol. 2004, 6:1221-1228.
42. Guo J.Y., Chen H.Y., Mathew R., Fan J., Strohecker A.M., Karsli-Uzunbas G., Kamphorst J.J., Chen G., Lemons J.M., Karantza V., Coller H.A., Dipaola R.S., Gelinas C., Rabinowitz J.D., White E. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Develop. 2011, 25:460-470.
43. Yang S., Wang X., Contino G., Liesa M., Sahin E., Ying H., Bause A., Li Y., Stommel J.M., Dell'antonio G., Mautner J., Tonon G., Haigis M., Shirihai O.S., Doglioni C., Bardeesy N., Kimmelman A.C. Pancreatic cancers require autophagy for tumor growth. Genes Develop. 2011, 25:717-729.
44. Elgendy M., Sheridan C., Brumatti G., Martin S.J. Oncogenic Ras-induced expression of Noxa and Beclin-1 promotes autophagic cell death and limits clonogenic survival. Mol. Cell 2011, 42:23-35.
45. Paraiso K.H., Fedorenko I.V., Cantini L.P., Munko A.C., Hall M., Sondak V.K., Messina J.L., Flaherty K.T., Smalley K.S. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Brit. J. Cancer 2010, 102:1724-1730.
46. Smalley K.S., Haass N.K., Brafford P.A., Lioni M., Flaherty K.T., Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol. Cancer Ther. 2006, 5:1136-1144.